Form 8-K

8-K — Cocrystal Pharma, Inc.

Accession: 0001493152-26-020586

Filed: 2026-04-30

Period: 2026-04-30

CIK: 0001412486

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001412486

2026-04-30

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): April 30, 2026

Cocrystal

Pharma, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-38418

35-2528215

(State

or other Jurisdiction

Incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

19805

N. Creek Parkway

Bothell,

98011

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (877) 262-7123

(Former

name or former address, if changed since last report.): n/a

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities

registered pursuant to Section 12(b) of the Act:

Title

of Each Class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock

COCP

The

Nasdaq Stock Market, LLC

(The

Nasdaq Capital Market)

Item

7.01 Regulation FD Disclosure.

April 30, 2026, Cocrystal Pharma, Inc. (the “Company”) issued a press release, announcing that the mechanism of action and

clinical advancement of its first oral protease inhibitor CDI-988 were featured today in an oral presentation at the 39th International

Conference on Antiviral Research (ICAR 2026) in Prague, Czech Republic. A copy of the press release is furnished as Exhibit 99.1.

The

information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under such section, and shall not be deemed

to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

Description

99.1

Press Release dated April 30, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Cocrystal

Pharma, Inc.

Date:

April 30, 2026

By:

/s/

James Martin

Name:

James

Martin

Title:

Co-Chief

Executive Officer and Chief Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Cocrystal

Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment

of Norovirus Infection

● Ongoing

Phase 1b human challenge study with oral, direct-acting protease inhibitor is designed to

demonstrate proof-of-concept as a preventive and a treatment

● Fully

enrolled first cohort is assessing the infectivity of the human challenge inoculum

● There

are no approved treatments or vaccines for norovirus, the leading cause of acute gastroenteritis

across all age groups and geographies with a $60 billion annual economic burden

● FDA

Fast Track designation granted for CDI-988 underscores the lack of approved therapies and

seriousness of norovirus infection

BOTHELL,

Wash. (April 30, 2026) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces

that the mechanism of action and clinical advancement of its first oral protease inhibitor CDI-988 were featured today in an oral presentation

at the 39th International Conference on Antiviral Research (ICAR 2026) in Prague, Czech Republic. The presentation, titled

“First Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: Novel Mechanism of Action and Phase

1 Study Results,” was delivered by Sam Lee, Ph.D., President and co-CEO of Cocrystal. Presentation slides are available on the

Company’s website here.

“It

was an honor to share our progress with CDI-988 with the global antiviral research community attending ICAR 2026,” said Dr. Lee.

“Following favorable Phase 1 data, we have advanced CDI-988 into a Phase 1b study under a human challenge model that provides an

efficient framework to rapidly demonstrate proof of concept as a preventive and as a treatment for norovirus infection. We have now completed

enrollment of the stage 1 study cohort, which will establish the infectivity rate of the GII.2 (Snow Mountain Virus) challenge inoculum.

This is a critical step in validating infectivity in the study cohorts.

“Multiple

norovirus vaccine clinical studies have been initiated over the past decade, yet none have led to an approval in part due to the virus’s

extensive genetic variation and drift, spanning 10 genogroups and 49 genotypes,” Dr. Lee added. “CDI-988 is designed to target

the highly conserved region of the 3CL protease across all known norovirus strains, including GII.4 and the re-emerging GII.17 variants,

as well as all coronaviruses. We believe this compound could offer a much-needed option for prevention and treatment in a convenient

oral formulation that can be readily stockpiled in advance of norovirus outbreaks.”

CDI-988

is a first, oral direct-acting antiviral and was developed using Cocrystal’s proprietary structure-based drug discovery platform

technology. As presented by Dr. Lee, in preclinical studies CDI-988 showed favorable gastrointestinal-targeted pharmacokinetics at the

site of norovirus infection and also demonstrated potent antiviral activity in GII.4-infected human enteronoid model systems.

a completed randomized, double-blind, placebo-controlled single- and multiple-ascending dose Phase 1 study in healthy adults, CDI-988

was generally safe and well tolerated across doses up to 1,200 mg, with headache as the most common treatment-emergent adverse event

and no serious adverse events reported. These results, together with a no-observed adverse effect of 1,000 mg/kg in GLP toxicology studies,

support CDI-988’s further clinical development in norovirus.

The

ongoing Phase 1b randomized, double-blind, placebo-controlled challenge study (NCT07198139) is being conducted at Emory University

School of Medicine in collaboration with the University of North Carolina. The study is designed to enroll up to 40 healthy adults, ages

18 to 49, in staged cohorts. The stage 1 infectivity cohort, now fully enrolled, will be followed by prevention and treatment cohorts

in which CDI-988 is administered at 1,200 mg twice daily for five days. The primary efficacy endpoint is reduction in the incidence of

clinical symptoms, with secondary endpoints including reduction in viral shedding, disease severity, safety and pharmacokinetics.

CDI-988

has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment and prophylaxis of norovirus

infection, underscoring the serious nature of norovirus disease and the lack of approved therapies. Fast Track status is intended to

facilitate development and expedite the review of drugs that address unmet medical needs, providing opportunities for more frequent FDA

interactions, rolling review of a potential New Drug Application and potential eligibility for Priority Review.

About

Norovirus

is the leading cause of acute gastroenteritis among all age groups and all geographic regions. It is highly contagious and causes symptoms

including nausea, vomiting, stomach pain, diarrhea, fatigue, fever and dehydration. It is notorious for outbreaks in semi-closed environments

such as hospitals, nursing homes, cruise ships, schools and military facilities. Norovirus is responsible for an estimated 685 million

cases and an estimated 200,000 deaths globally each year, with an approximate $60 billion in worldwide economic impact. In the United

States alone, the virus is associated with 21 million infections annually, resulting in around 109,000 hospitalizations, 465,000 emergency

department visits and 900 deaths. The estimated annual economic burden in the U.S. exceeds $10.6 billion. In developing nations,

norovirus contributes up to 1.1 million hospitalizations and 218,000 pediatric deaths each year.

About

ICAR

Hosted

by the International Society for Antiviral Research (ISAR), the International Conference on Antiviral Research (ICAR) brings together

leading scientists, researchers and industry professionals from around the world to discuss the latest advancements and breakthroughs

in antiviral research. ICAR provides a variety of networking opportunities allowing members to connect with colleagues and establish

new scientific relationships and collaborations with leaders in the antiviral field.

About

Cocrystal Pharma, Inc.

Cocrystal

Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication

process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and rhinoviruses. Cocrystal employs unique structure-based

technologies and Nobel Prize-winning expertise to create viable antiviral drugs. For further information about Cocrystal, please visit

www.cocrystalpharma.com.

Cautionary

Note Regarding Forward-Looking Statements

This

press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including

statements regarding any implications that CDI-988 is able to prevent and/or treat norovirus infections. The words “believe,”

“may,” “estimate,” “continue,” “anticipate,” “intend,” “should,”

“plan,” “could,” “target,” “potential,” “is likely,” “will,”

“expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based

these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated

by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking

statements include, but are not limited to, the risks and uncertainties arising from delays arising

from raw materials and labor shortages, supply chain disruptions and other business interruptions including any adverse impacts on our

ability to obtain raw materials for and otherwise proceed with studies as well as similar problems with our vendors and our current and

any future clinical research organization (CROs) and contract manufacturing organizations, the progress and results of the studies including

any adverse findings or delays, the ability of us and our CROs to recruit volunteers for, and to otherwise proceed with, clinical studies,

our and our collaboration partners’ technology and software performing as expected, financial difficulties experienced by certain

partners, the results of any current and future preclinical and clinical studies, general risks arising from clinical studies, receipt

of regulatory approvals, regulatory changes and any adverse developments which may arise therefrom, and general economic adverse effects

from the ongoing conflict with Iran. Further information on our risk factors is contained in our filings with the SEC, including

the “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. Any forward-looking

statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to

differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update

any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by

law.

Investor

Contact:

Alliance

Advisors IR

Jody

Cain

310-691-7100

jcain@allianceadvisors.com

# #

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (14524 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Apr. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 30, 2026

Entity File Number

001-38418

Entity Registrant Name

Cocrystal

Pharma, Inc.

Entity Central Index Key

0001412486

Entity Tax Identification Number

35-2528215

Entity Incorporation, State or Country Code

Entity Address, Address Line One

19805

N. Creek Parkway

Entity Address, City or Town

Bothell

Entity Address, State or Province

Entity Address, Postal Zip Code

98011

City Area Code

(877)

Local Phone Number

262-7123

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock

Trading Symbol

COCP

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration